The current status of homocysteine as a risk factor for cardiovascular disease: a mini review

References

• Mudd SH. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol. 2002;20:1704–1706.
   Web of Science ®Google Scholar
• The Nobel Prize in Chemistry. [cited 2018 June 20]. Available from: http://www.nobelprize.org/nobel_prize/chemistry/laureates/1955
   Google Scholar
• McCully KS, Ragsdale BD. Production of arteriosclerosis by homocysteinemia. Am J Pathol. 1970;61:1–11.
   PubMed Web of Science ®Google Scholar
• Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976;57:1079–1082.
   PubMed Web of Science ®Google Scholar
• Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236.
   PubMed Web of Science ®Google Scholar
• Clarke R, Collins R, Arnesen E, et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022.
   PubMed Web of Science ®Google Scholar
• Malinow MR, Bostom AG, Kraus RM. Homocysteine, diet, and cardiovascular disease: a statement for health care professionals, from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178–182.
   PubMed Web of Science ®Google Scholar
• Booth GL, Wang EE. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. CMAJ. 2000;163:21–29.
   PubMed Web of Science ®Google Scholar
• Jacques PF, Selhub J, Bostom AG. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449–1454.
   PubMed Web of Science ®Google Scholar
• Mei W, Rong Y, Jinming L, et al. Effect of homocysteine interventions on the risk of cardiocerebral events: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2010;64:208–215.
   PubMed Web of Science ®Google Scholar
• Wong YY, Golledge J, Flicker L, et al. Plasma total homocysteine is associated with abdominal aortic aneurysm and aortic diameter in older men. J Vasc Surg. 2013;58:364–367.
   PubMedGoogle Scholar
• Zhang S, Bai YY, Luo LM, et al. Association between serum homocysteine and arterial stiffness in the elderly: a community-based study. J Geriatr Cardiol. 2014;11:32–38.
   PubMedGoogle Scholar
• Schaffer A, Verdoia M, Cassetti E, et al. Relationship between homocysteine and coronary artery disease. Results from a large prospective study. Thromb Res. 2014;134:288–293.
   PubMed Web of Science ®Google Scholar
• Hankey GJ. B vitamins for stroke prevention. Stroke Vasc Neur. 2018:e000156.
   Google Scholar
• Cui R, Iso H, Date C, et al. Dietary folate and vitamin B6, and B12 intake in relation to mortality from cardiovascular diseases. Japan Collaborative Cohort Study. Stroke. 2010;41:1285–1289.
   PubMed Web of Science ®Google Scholar
• Wang ZM, Zhou B, Nie ZL, et al., Folate and risk of coronary heart disease: a meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2012; 22: 890–899.
   PubMed Web of Science ®Google Scholar
• Huang T, Chen Y, Yang B, et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr. 2012;31:448–454.
   PubMed Web of Science ®Google Scholar
• Qin X, Huo Y, Xie D, et al. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr. 2013;32:722–727.
   PubMed Web of Science ®Google Scholar
• Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China. The CSPPT randomized trial. JAMA. 2015;313:1325–1335.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang T, Zheng Y, et al., Folic acid supplementation and the risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016; 5: e003768.
   PubMed Web of Science ®Google Scholar
• Park JH, Saposnik G, Ovbiagele B, et al., Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: a meta-analysis. Int J Stroke. 2016; 11: 206–211.
   PubMed Web of Science ®Google Scholar
• Wang WW, Wang XS, Zhang ZR, et al. A meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and hyperhomocysteinemia. Front Pharmacol. 2017;8:585.
   PubMed Web of Science ®Google Scholar
• Tan T, Yang KQ, Cui JG, et al. Folic acid supplementation for stroke prevention in patients with cardiovascular disease. Am J Med Sci. 2017;354:379–387.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303:2486–2494.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bonaa KH, Arnessen E, et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268:367–382.
   PubMed Web of Science ®Google Scholar
• Loland KH, Bleie O, Blix AJ, et al. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. Am J Cardiol. 2010;105:1577–1584.
   PubMed Web of Science ®Google Scholar
• Clarke R, Halsey J, Lewington S, et al., Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause-specific mortality. Arch Intern Med. 2010; 170: 1622–1631.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One. 2011;6:e25142.
   PubMed Web of Science ®Google Scholar
• Lee M, Hong KS, Chang SC, et al. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention. A meta-analysis. Stroke. 41: 1205–1212.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: a systematic review and meta-analysis. BMJ. 2012;344:e3533.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang ZY, Qin YY, et al. Association between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta-analysis of randomized controlled trials. PLos-One. 2014;9:e107060.
   PubMed Web of Science ®Google Scholar
• Marti-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017(8):CD006612.
   Google Scholar
• Christen WG, Ajani UA, Glynn RJ, et al. Blood levels of homocysteine and increased risks of cardiovascular disease. Arch Intern Med. 2000;160:422–434.
   PubMed Web of Science ®Google Scholar
• Kwon HM, Lee YS, Bae HJ, et al. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014;45:871–873.
   PubMed Web of Science ®Google Scholar
• Curro M, Gugliandolo A, Gangemi C, et al. Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res. 2014;39:1485–1495.
   PubMed Web of Science ®Google Scholar
• Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.
   PubMed Web of Science ®Google Scholar
• Spence D. Mechanisms of thrombogenesis in atrial fibrillation. Lancet. 2009;373:1006.
   PubMedGoogle Scholar
• Spence JD, Hankey QY. B vitamins in stroke prevention: time to reconsider. Lancet Neur. 2017;16:750–760.
   PubMed Web of Science ®Google Scholar
• Faeh D, Chiolero A, Pascaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about it? Swiss Med Wkly. 2006;136:745–756.
   PubMed Web of Science ®Google Scholar
• Vereenna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol. 2011;58:1025–1033.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yong YB, Luo IM, et al. Assocition between serum homocysteine and arterial stiffness in elderly: a community-based study. J Geriatr Cardiol. 2014;11:32–38.
   PubMedGoogle Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006;113:e463–e654.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Chiu SW, Hong KS, et al. Folic acid in stroke prevention in countries without mandatory folic acid food fortification: A meta-analysis of randomized controlled trials. J Stroke. 2018;20:99–109.
   PubMed Web of Science ®Google Scholar
• Zhao M, Wu G, Li Y, et al. Meta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers. Neurology. 2017;88:1830–1838.
   PubMed Web of Science ®Google Scholar
• Huang X, Li Y, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke. Neurology. 2017;89:2101–2107.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
   PubMed Web of Science ®Google Scholar